BioCardia, Inc. 8-K

What Happened
BioCardia, Inc. (BCDA) reported on April 2, 2026, that it submitted clinical study data from its CardiAMP HF program to the U.S. Food and Drug Administration (FDA). The company said it plans to meet with the FDA to discuss pursuing the accelerated approval pathway for the CardiAMP® System to treat ischemic chronic heart failure with reduced ejection fraction (HFrEF). A company press release announcing these actions was attached to the Form 8-K as Exhibit 99.1.

Key Details

• Filing date: April 2, 2026 (Form 8-K Item 7.01, Regulation FD Disclosure).
• Submission: Clinical study data from the CardiAMP HF study submitted to FDA.
• Regulatory step: BioCardia plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System for ischemic chronic HFrEF.
• Press release: Company press release dated April 2, 2026 attached as Exhibit 99.1.

Why It Matters
This is a regulatory progress update: submission of clinical data and a planned FDA meeting are material steps toward potential approval. If the FDA supports an accelerated approval pathway, it could shorten the time to market for the CardiAMP System—affecting BioCardia’s commercial prospects. The filing does not provide results, timing, or guarantees of approval; investors should view this as a forward step in the regulatory process rather than a final outcome.